In its 13th Annual Dealmakers’
“Entering 2023, the investment and dealmaking environment remains complicated and slightly unclear, despite witnessing a bounty of research and regulatory milestones,” said
Key findings from this year’s report include:
- While large pharma is looking to expand portfolios, many remain cautious. That said, restructuring efforts across the sector could position these leaders to come back strong in dealmaking in the second half of 2023.
- Cancer vaccines, RNA targeted therapies and immuno-oncology saw the largest increase in interest from the prior year. Additionally, COVID-19 treatments, CAR-T and gene editing therapies remain areas of high interest among dealmakers.
- Interest in cell and gene therapy technologies remains strong heading into 2023, with 65 percent of survey respondents stating that they are actively seeking deals in this area.
- A focus on digital health technologies remains strong with approximately 33 percent of survey respondents stating that they are actively seeking deals or that it remains a cornerstone of their dealmaking strategy.
To learn more:
- Download the full 2023 Dealmakers’
Intentions Survey . - Submit a request to have a
Syneos Health Consulting team member present survey results and implications for your business. - Subscribe to the
Syneos Health podcast where the study experts will provide further analysis of the survey results.
About
We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics.
Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.
To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.
Investor Relations Contact: | Press/Media Contact: | ||
Senior Vice President, Investor Relations | Executive Director, | ||
+1 919 745 2745 | +1 908 763 3428 | ||
Investor.Relations@syneoshealth.com | gary.gatyas@syneoshealth.com |
Source:
2023 GlobeNewswire, Inc., source